Motley Fool
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million
📊
AI Sentiment
Positive
6/10
- Home
- NRIX
as of 02-24-2026 9:34am EST
$15.74
+$0.36
+2.34%
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 1.7B | IPO Year: | 2020 |
| Target Price: | $29.46 | AVG Volume (30 days): | 844.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | semi-annual |
| EPS: | -3.05 | EPS Growth: | -5.90 |
| 52 Week Low/High: | $8.18 - $22.50 | Next Earning Date: | 05-01-2026 |
| Revenue: | $76,987,000 | Revenue Growth: | 99.31% |
| Revenue Growth (this year): | -23.88% | Revenue Growth (next year): | 29.30% |
| P/E Ratio: | -5.04 | Index: | N/A |
| Free Cash Flow: | -263467000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Nurix Therapeutics Inc. (NRIX)
Ring Christine
Sell
Chief Legal Officer
NRIX Feb 9, 2026
Avg Cost/Share
$16.66
Shares
14,261
Total Value
$237,618.21
Owned After
42,749
SEC Form 4
Ring Christine
Sell
Chief Legal Officer
NRIX Jan 20, 2026
Avg Cost/Share
$18.42
Shares
3,760
Total Value
$69,273.11
Owned After
42,749
SEC Form 4
Ring Christine
Sell
Chief Legal Officer
NRIX Dec 18, 2025
Avg Cost/Share
$18.21
Shares
3,760
Total Value
$67,314.32
Owned After
42,749
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Ring Christine | NRIX | Chief Legal Officer | Feb 9, 2026 | Sell | $16.66 | 14,261 | $237,618.21 | 42,749 | |
| Ring Christine | NRIX | Chief Legal Officer | Jan 20, 2026 | Sell | $18.42 | 3,760 | $69,273.11 | 42,749 | |
| Ring Christine | NRIX | Chief Legal Officer | Dec 18, 2025 | Sell | $18.21 | 3,760 | $67,314.32 | 42,749 |
Latest Nurix Therapeutics Inc. News
NRIX Breaking Stock News: Dive into NRIX Ticker-Specific Updates for Smart Investing
Motley Fool
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%
📈
AI Sentiment
Highly Positive
9/10
Motley Fool
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year
âž–
AI Sentiment
Neutral
4/10
Motley Fool
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025
📈
AI Sentiment
Highly Positive
9/10
Motley Fool
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%
📈
AI Sentiment
Highly Positive
8/10
Compare NRIX vs Leading Stocks
See how NRIX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NRIX Nurix Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.